Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Virginia: above-average open trial sites
1,028 of 2,598 in-state trials are recruiting (40%); above the 37% national average by 3 percentage points, with Phase 2 weight.
According to ClinicalTrials.gov-derived indexes, Virginia sits in the upper half of US states by in-state trial count (#23 of 52 states by registered in-state trial count).
Virginia: 2,598 US clinical trials with in-state sites, 1,028 recruiting.
Virginia has 2,598 registered US clinical trials with a study site in-state, 1,028 of them currently recruiting (above the 37% national average by 3 percentage points). 381 of these trials are in Phase 3 (late-stage) and 582 in Phase 2. The most frequently studied condition in Virginia is Non-Small Cell Lung Cancer, with 84 linked trials.
Mid-pack research density
Virginia sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Above-average open enrollment
Virginia currently lists 1,028 recruiting sites across 2,598 in-state trials (40% open): above the 37% national average by 3 percentage points, so open slots are denser than the registry-wide mix.
- 1,028
- recruiting now (above-average share)
- 40%
- open vs national baseline
- 381
- Phase 3 rows in this footprint
- 84
- top: Non-Small Cell Lung Cancer
Recruiting share is above the 37% national average by 3 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Virginia vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
2,598 Top 44% more indexed trials than 56% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Virginia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Virginia open-enrollment share sits above the national baseline.
1,028 of 2,598 in-state trials (39.6%) are recruiting, against 37% nationally (+2.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Virginia trial sites spread across 8 city hubs.
Richmond lists 667 of 2,598 in-state trials (25.7%) across 212 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Non-Small Cell Lung Cancer is the most-studied condition in Virginia.
84 of 2,598 in-state trials (3.2%) list Non-Small Cell Lung Cancer. That is a local concentration figure, not a national disease ranking.
-
Virginia sponsorship is fragmented across many organizations.
University of Virginia appears on 173 of 2,598 in-state trials (6.7%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,025 Virginia trials carry a completed status.
1,025 of 2,598 (39.5%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Recruiting | 1,028 |
| Completed | 1,025 |
| Active | 545 |
By Phase
| Phase | Trial count |
|---|---|
| NA | 623 |
| Phase 2 | 582 |
| Phase 1 | 557 |
| Phase 3 | 381 |
| Phase 4 | 108 |
| Early Phase 1 | 17 |
Top Conditions
Top Sponsors
Where trials run in Virginia
Richmond carries 667 of Virginia's 2,598 indexed trials (26%) across 212 named sites, ahead of Charlottesville at 637. 8 cities clear five listed trials, together naming 864 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Richmond | 667 | 212 |
| Charlottesville | 637 | 141 |
| Fairfax | 499 | 188 |
| Norfolk | 322 | 158 |
| Roanoke | 109 | 58 |
| Falls Church | 90 | 37 |
| Virginia Beach | 58 | 41 |
| Lynchburg | 43 | 29 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share high
Virginia open-enrollment share is 40% (p98 of states with sites; national baseline 37%).
Virginia: open share sits in the high tercile of states
Sites spread across 8 cities with five or more listed trials, led by Richmond (667, 26% of the state total) and Charlottesville (637), together naming 864 distinct research locations.
Phase mix: 381 Phase 3 vs 582 Phase 2 (early-phase heavy).
Top condition: Non-Small Cell Lung Cancer (84 trials); top sponsor University of Virginia (173).
mid-volume · high-open figures (2,598 trials · 40% open) describe registry geography under the open-share high read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Virginia on open-enrollment share
Cross-state peers under the open-share high read (mid-volume · high-open), not the same-state browse list.
Similar mid-volume peers (± open share)
- Washington · 2,795 trials · 33% recruiting
- Arkansas · 2,376 trials · 28% recruiting
- District of Columbia · 2,316 trials · 31% recruiting
- Kentucky · 2,183 trials · 32% recruiting
- Indiana · 3,113 trials · 29% recruiting
Similar high-open peers (± trial volume)
- Utah · 38% recruiting · 1,734 trials
- Texas · 37% recruiting · 9,951 trials
- Wisconsin · 37% recruiting · 1,760 trials
- West Virginia · 36% recruiting · 277 trials
- Minnesota · 36% recruiting · 4,506 trials